Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 8
Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy
Authors Rizzardini G, Bonfanti P, Carenzi, Coen, Orlando, Di Matteo S, Colombo G
Received 7 May 2012
Accepted for publication 16 July 2012
Published 17 September 2012 Volume 2012:8 Pages 377—384
DOI https://doi.org/10.2147/TCRM.S33674
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Giuliano Rizzardini,1 Paolo Bonfanti,2 Laura Carenzi,1 Massimo Coen,1 Giovanna Orlando,1 Sergio Di Matteo,3 Giorgio L Colombo3,4
11st Infectious Diseases Department, “L. Sacco” Hospital, Milan, Italy; 2Infectious Diseases Department, A Manzoni Hospital, Lecco, Italy; 3S.A.V.E. Studi Analisi Valutazioni Economiche, Milan, Italy; 4University of Pavia, Department of Drug Sciences, School of Pharmacy, Italy
Introduction: We carried out an economic analysis to assess the cost-effectiveness of highly active antiretroviral therapy (HAART) regimens in Italy for the management of human immunodeficiency virus (HIV)-infected patients according to clinical practice in the Infectious Diseases Department of “L. Sacco” Hospital, Milan, Italy.
Patients and methods: The incremental cost-effectiveness analysis was completed by means of a Markov model. Through a decision-analytic approach, this enabled us to compare the studied antiretroviral regimens. The model considered a population of adult HIV subjects who received HAART therapy for the first time according to clinical practice in the Infectious Diseases Department of “L. Sacco” Hospital, Milan. Data were investigated from the standpoint of the Lombardy Regional Health Service. We considered the following outcome measures: quality-adjusted life-years (QALYs), and direct health costs calculated for the years 2008 and 2009. The time horizon adopted in the model was 2 years.
Results: The model revealed that, in terms of cost per gained QALY, the tenofovir disoproxil fumarate + emtricitabine + efavirenz (TDF+FTC+EFV) once-a-day treatment strategy seems to be the most cost-effective therapeutic choice (€34,965); the incremental cost-effectiveness ratio (ICER) values for the remaining strategies ranged from €53,000 to around €62,000 per QALY. The validity of the base case scenario was then confirmed by means of a sensitivity analysis on the main variables.
Conclusion: The TDF+FTC+EFV treatment strategy (TDF/FTC+EFV fixed-dose combination then switched to single-tablet regimen [STR]) in this setting is the most cost-effective treatment strategy compared with the other therapeutic regimens. The ICER value for the TDF+FTC+EFV once-a-day then switched to STR treatment was lower than the internationally generally accepted threshold value of €50,000. The developed model is a tool for policy makers and health care professionals for creating short- and long-term cost projections, with the aim of assessing their impact on the available budgets for HIV patients.
Keywords: AIDS, HIV, HAART antiretroviral therapy regimens, single-tablet regimen (STR), Markov model, cost-effectiveness, quality-adjusted life-years, QALYs
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.